PCSK 9 Inhibitors: A Short History and a New Era of Lipid-lowering Therapy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

28 citing papers in PubMed, 3 syntheses or guidelines pooled it.

1. Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease: A Network Meta-analysis.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026 · on this map
   Pooled it
2. Efficacy and safety of PCSK-9 inhibitors in patients with acute coronary syndrome: a systematic review and network meta-analysis.BMC cardiovascular disorders · 2025 · on this map
   Pooled it
3. The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis.Current cardiology reviews · 2025
   Pooled it
4. Associations of plasma inosine with lipid parameters in a biracial community cohort.Clinical nutrition (Edinburgh, Scotland) · 2025
   Trial
5. Are RNA Therapies a Solid Foundation or a Frontier Yet to Be Conquered?International journal of molecular sciences · 2026
   Review
6. A comprehensive overview of the biological foundations of ADHD.Bioscience reports · 2026
   Review
7. The effect of PCSK9 inhibitors on cardiovascular outcomes in diabetic patients: a narrative review.Frontiers in pharmacology · 2026
   Review
8. Translational Nanomedicine and Delivery Tools for Cardiovascular Disease Therapy and Diagnostics.Advances in experimental medicine and biology · 2026
   Review
9. A genetics-guided integrative framework for drug repurposing: identifying antihypertensive drugs for type 2 diabetes.NPJ drug discovery · 2026
   Article
10. Integrated Transcriptome and Metabolome Analyses Uncover Cholesterol-Responsive Gene Networks.International journal of molecular sciences · 2025
    Article
11. Genomic and Precision Medicine Approaches in Atherosclerotic Cardiovascular Disease: From Risk Prediction to Therapy-A Review.Biomedicines · 2025
    Review
12. Oral and Non-Oral Cholesterol-Lowering Drugs with PCSK9 and Other Biomolecules as Targets: Present Status and Future Prospects.Biomolecules · 2025
    Review
13. PCSK9 levels and diabetic retinopathy: opportunities for a potential target and novel therapeutic approach in conjunction with treating dyslipidaemia.Eye (London, England) · 2025
    Article
14. Metabolic Status Modulates Global and Local Brain Age Estimates in Overweight and Obese Adults.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2025
    Article
15. Targeting fatty acid synthase reduces aortic atherosclerosis and inflammation.Communications biology · 2025
    Article
16. Current usage of inclisiran for cardiovascular diseases: overview of current clinical trials.Frontiers in pharmacology · 2025
    Review
17. Use and effectiveness of PCSK-9 inhibitors in heart diseases: A review.Medicine · 2024
    Review
18. A Comparative Analysis of Low-Density Lipoprotein Cholesterol (LDL-C)-Lowering Activities of Bempedoic Acid, Inclisiran, and PCSK9 Inhibitors: A Systematic Review.Cureus · 2024
    Review
19. Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons.Endocrine · 2024
    Review
20. The Pleiotropic Effects of Lipid-Modifying Interventions: Exploring Traditional and Emerging Hypolipidemic Therapies.Metabolites · 2024
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.